1 min read
Retension Pharmaceuticals Posts $7.33 Q3 GAAP Loss Per Share
Cash and cash equivalents totaled $9.2 million at Sept. 30, excluding about $45.1 million in net IPO proceeds from a deal that closed after the quarter.

Retension Pharmaceuticals, Inc. (RTSN) recorded a GAAP loss of $7.33 per share for the third quarter of 2026. Cash and cash equivalents totaled $9.2 million on Sept. 30, compared with $18.9 million on Dec. 31, 2025.
The quarter-end cash balance excludes net proceeds from the company’s IPO, which closed after the quarter. On a pro forma basis, including about $45.1 million in net IPO proceeds, cash and cash equivalents as of Sept. 30 were about $54.3 million.